LARTRUVO
PeakmAbBLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARTRUVO is a monoclonal antibody (mAb) therapeutic approved by the FDA in October 2016 as an injectable biologic. The specific indication, mechanism of action, and patient population are not publicly disclosed in available data.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30/100), indicating a stable but non-dominant market position requiring focused commercial execution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARTRUVO is a peak-stage mAb with no currently linked job openings, but its peak lifecycle stage and moderate competitive environment suggest ongoing needs for experienced commercial, medical affairs, and market access professionals. Working on this product offers exposure to mature biologic commercialization and competitive differentiation strategies.
Brand ManagerMedical Science Liaison
Worked on LARTRUVO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.